drugset / Trial / NCT00538980
Dasatinib in Polycythemia Vera
Phase 2
Terminated
10 enrolled
Weill Medical College of Cornell University
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose for conducting this research study is to determine the feasibility of using dasatinib as a treatment for polycythemia vera and to determine the optimum treatment regimen.
Timeline
- Start
- 2007-04-30
- Primary completion
- 2010-08-25
- Completion
- 2010-08-27
Outcome
Outcome not reported
Stopped: “This study was terminated due to lack of efficacy.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 120 mg | Oral |